protocolSection identificationModule nctId: NCT06278519, orgStudyIdInfo id: CARAMBOLE, briefTitle: CARdiAc Mri and BiOLogical samplEs at the Acute Phase of a Myocardial Infarction (CARAMBOLE), acronym: CARAMBOLE, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2026-09-01, completionDateStruct date: 2026-09-01, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-03-12, sponsorCollaboratorsModule leadSponsor name: Poitiers University Hospital, class: OTHER, collaborators name: Fédération Française de Cardiologie, descriptionModule briefSummary: ST-Segment Elevation Myocardial infarction (STEMI) corresponding to acute occlusion of cornary artery is the most severe ischemic myocardial disease and a leading cause of mortality of heart failure worldwide. Although acute mortality from STEMI has decreased over the last decades, the prognosis remains pejorative and difficult to anticipate. The best management of STEMI patients depends of predictive factors of clinical prognosis and justifies an active research of these factors, in particular the mechanisms leading to deleterious left ventricular remodeling, myocardial inflammation, reperfusion injury including the no-reflow phenomenon which is a major determinant of heart failure. Cohorts of consecutive STEMI patients, with a comprehensive assessment of clinical, biological and imaging parameters are needed to offer the basis for new hypothese for research or interventions and to precisely evaluate the quality of care provided.The main objective of this study is to identify new markers: clinical, biological and imaging, treatment response and prognosis after STEMI.Secondary objectives of the CARAMBOLE cohort are to establish a comprehensive clinical databse, completed with biological samples and imaging data, that can be used in the following areas:* Descriptive epidemiology of STEMI and myocardial reperfusion* Evaluation of the clinical implications of the realization of a cardiac MRI at the acute phase of STEMI (regarding no-reflow, LVEF, intra cardiac thrombi)* Treatments observatory: safety, efficacy, indication of treatments provided in real life compared to the treatments recommended, adherence to treatments, costs* Quality of life, personal, familial, social and professional consequences of myocardial infarction* Research of new diagnostic and prognosis biomarkers* Research projects (e.g risk of developping cgnitive disorders in patients with STEMI as compared to the general population)Participants will undergo:* a cardiac MRI at the acute phase of their STEMI (5 +/- 3 days) then at 1 year follow-up* biological samples including blood, urinary and feces samples, at the acute phase of their STEMI (from admission and up to 8 days) then at 1 year follow-up* questionnaire assessment regarding their quality of life, cognitive status,and socio-economic conditions at the acute phase and 1 year follow-up of their STEMI., conditionsModule conditions: Myocardial Infarction, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: NONE, enrollmentInfo count: 150, type: ESTIMATED, armsInterventionsModule interventions name: Blood, urinary and feces collection, interventions name: Cardiac MRI, interventions name: Quality of life and cognitive status questionnaire, outcomesModule primaryOutcomes measure: Major Adverse cardiac Events (MACE), secondaryOutcomes measure: Infarct size, secondaryOutcomes measure: Infarct size, secondaryOutcomes measure: No-reflow size, secondaryOutcomes measure: No-reflow size, secondaryOutcomes measure: Cardiac enzymes rate, secondaryOutcomes measure: Cardiac enzymes rate, secondaryOutcomes measure: Cardiac enzymes rate, secondaryOutcomes measure: Cardiac enzymes rate, secondaryOutcomes measure: Inflammatory markers rate, secondaryOutcomes measure: Inflammatory markers rate, secondaryOutcomes measure: Inflammatory markers rate, secondaryOutcomes measure: Inflammatory markers rate, secondaryOutcomes measure: Gut microbiota profiling, secondaryOutcomes measure: Gut microbiota profiling, secondaryOutcomes measure: Genitourinary microbiota profiling, secondaryOutcomes measure: Genitourinary microbiota profiling, secondaryOutcomes measure: EQ-5D-3L score (European Quality of Life 5 Dimensions 3 Level version), secondaryOutcomes measure: EQ-5D-3L score (European Quality of Life 5 Dimensions 3 Level version), secondaryOutcomes measure: Codex test, secondaryOutcomes measure: Codex test, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: C.H.U. of Poitiers, status: RECRUITING, city: Poitiers, zip: 86000, country: France, contacts name: Claire BOULETI, MD, role: CONTACT, phone: +33 5 49 44 43 25, email: claire.bouleti@chu-poitiers.fr, geoPoint lat: 46.58333, lon: 0.33333, hasResults: False